<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01867697</url>
  </required_header>
  <id_info>
    <org_study_id>Nordic 8</org_study_id>
    <nct_id>NCT01867697</nct_id>
  </id_info>
  <brief_title>Nordic 8 - A Phase II Trial</brief_title>
  <official_title>Potentially Resectable Metastatic Colorectal Cancer With Wild-type KRAS and BRAF: Alternating Chemotherapy Plus Cetuximab - A Randomised Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Pfeiffer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono International SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nordic randomized phase II trial which evaluates whether biweekly cetuximab with alternating&#xD;
      FOLFIRI and mFOLFOX6 is more effective than biweekly cetuximab with continuously FOLFIRI in&#xD;
      patients with potential resectable KRAS wildtype metastatic colorectal cancer.&#xD;
&#xD;
      All patients will be randomized to biweekly cetuximab 500 mg/m2 in combination with arm A)&#xD;
      FOLFIRI (irinotecan 180 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46&#xD;
      hours 5FU infusion of 2400 mg/m2 every 2 weeks) or arm B) FOLFIRI alternating with FOLFOX6&#xD;
      (Oxaliplatin: 85 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU&#xD;
      infusion of 2400 mg/m2 every 2 weeks) .&#xD;
&#xD;
      Primary objective: response rate (RECIST 1.1) in patients with with potential resectable KRAS&#xD;
      wildtype metastatic colorectal cancer.&#xD;
&#xD;
      Secondary objectives: Resection rate, PFS, OS, Quality of life, tolerability. Biomarker&#xD;
      evaluation to measure plasma biomarkers, Tumour blocks and sequential serum and plasma will&#xD;
      be collected to search for markers that may predict efficacy including respectability and&#xD;
      safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2012</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>March 2015 (up to 3 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival (Overall survival)</measure>
    <time_frame>June 2016 (up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of secondary surgical resection (R0 + R1 + R2 resections)</measure>
    <time_frame>January 2015 (up to 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of secondary micro-radical surgical resection (R0 resection)</measure>
    <time_frame>March 2015 (up to 3 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Biweekly cetuximab with continuously FOLFIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI (irinotecan 180 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI alternating with FOLFOX6 (Oxaliplatin: 85 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6</arm_group_label>
    <arm_group_label>Biweekly cetuximab with continuously FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6</arm_group_label>
    <arm_group_label>Biweekly cetuximab with continuously FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <arm_group_label>Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6</arm_group_label>
    <arm_group_label>Biweekly cetuximab with continuously FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Carbonate</intervention_name>
    <arm_group_label>Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6</arm_group_label>
    <arm_group_label>Biweekly cetuximab with continuously FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Histology and stages:&#xD;
&#xD;
          -  Histologically proven adenocarcinoma in the colon or rectum&#xD;
&#xD;
          -  At least 1 measurable metastatic disease manifestation according to the RECIST&#xD;
             criteria (version 1.1)&#xD;
&#xD;
          -  Potentially completely resectable or potentially curable metastatic colorectal cancer&#xD;
             as determined by the local MDT conference and that requires tumour shrinkage before&#xD;
             resection is possible. The following definitions are indicative:&#xD;
&#xD;
               -  4 or more liver metastases (CRLeM) without extra-hepatic disease&#xD;
&#xD;
               -  2 or more lung metastases (CRLuM) without hepatic or extra-hepatic disease&#xD;
&#xD;
               -  1 or more CRLeM determined as &quot;potentially resectable&quot; (such as because of&#xD;
                  location) by the local MDT.&#xD;
&#xD;
               -  1 or more CRLuM determined by the local MDT as potentially resectable (such as&#xD;
                  because of location).&#xD;
&#xD;
               -  Non-resectable primary disease with resectable CRLeM or CRLuM.&#xD;
&#xD;
        KRAS and BRAF status:&#xD;
&#xD;
        - Tumour tissue (primary or metastasis) typed as wild-type KRAS AND wild-type BRAF&#xD;
&#xD;
        General conditions:&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
          -  WHO performance status ≤ 1&#xD;
&#xD;
          -  expected survival &gt; 3 months&#xD;
&#xD;
          -  sufficient bone-marrow function (Hb ≥ 6.2 µmol/l/Hb &gt; 10 g/dl ANC ≥ 1.5 x 109/l,&#xD;
             thrombocytes ≥ 100 x 109/l)&#xD;
&#xD;
          -  sufficient kidney and liver function: total bilirubin ≤ 1.5 x upper normal limit,&#xD;
             serum creatinine ≤ 1.25 x upper normal limit, ALAT ≤ 3 x upper normal limit and ≤ 5 x&#xD;
             upper normal limit with liver metastases&#xD;
&#xD;
          -  the patient must have signed an informed declaration of consent before being&#xD;
             registered; this must be documentable according to national guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Previous treatment:&#xD;
&#xD;
          -  previous chemotherapy for advanced/metastatic disease&#xD;
&#xD;
          -  adjuvant chemotherapy unless completed more than 6 months before registration&#xD;
&#xD;
          -  previous treatment with oxaliplatin or irinotecan&#xD;
&#xD;
          -  previous treatment with cetuximab or other treatment for EGFR&#xD;
&#xD;
          -  History of Inflammatory Bowel disease&#xD;
&#xD;
          -  Severe or uncontrolled cardiovascular disease, congestive heart failure NYHA III or&#xD;
             IV, unstable angina pectoris, history of myocardial infarction within the last twelve&#xD;
             months, significant arrhythmias)&#xD;
&#xD;
          -  Any condition that, according to the treating physician's judgement, could prevent the&#xD;
             planned medical/surgical treatment from being carried out responsibly (such as&#xD;
             uncontrolled active infection, known hypersensitivity or contra-indication for the&#xD;
             planned treatment.&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Patients of fertile age who do not want to use reliable contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Pfeiffer, Professor, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Halfdan Sørbye, Professor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bengt Glimelius, Professor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akademiske Sygehus, Uppsala University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydvestjysk Hospital</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herning Hospital</name>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naestved Hospital</name>
      <address>
        <city>Naestved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trondheim University Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 21, 2012</study_first_submitted>
  <study_first_submitted_qc>June 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2013</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Per Pfeiffer</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

